

# Is ART use associated with increased risk of ALT elevation in HIV/HCV co-infected patients over and above what is expected in HIV mono-infected: a nested case control study approach

<sup>1</sup>Shanyinde M, <sup>2</sup>Marchetti G, <sup>3</sup>Bruno R, <sup>4</sup>Ceccherini-Silberstein F, <sup>5</sup>Gori A, <sup>6</sup>De Luca A, <sup>7</sup>Vecchiet J, <sup>8</sup>Lichtner M, <sup>9</sup>Madeddu G, <sup>10</sup>Bonfanti P, <sup>11</sup>D'Arminio Monforte A and <sup>1</sup>Cozzi-Lepri A on behalf of the ICONA Foundation Study group

<sup>1</sup>Department of Infection & Population Health Division of Population Health, University College London, London, United Kingdom; <sup>2</sup>Clinic of Infectious Diseases, Department of Health Sciences, University of Milan, San Paolo Hospital, Milan, Italy;

<sup>3</sup>Department of Infectious Diseases, University of Pavia Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; <sup>4</sup>University of Rome Tor Vergata, Department of Experimental Medicine, Roma, Italy; <sup>5</sup>Infectious Diseases Clinic, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; <sup>6</sup>Siena University Hospital, Infectious Diseases Unit, Siena, Italy; <sup>7</sup>Clinic of Infectious Diseases, University of Chieti, Chieti, Italy; <sup>8</sup>Clinic of Infectious Diseases, La Sapienza University, Rome, Italy; <sup>9</sup>Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy; <sup>10</sup>Azienda Ospedaliera Lecco, Department of Infectious Diseases, Lecco, Italy; <sup>11</sup>Clinic of Infectious Diseases, Department of Health Sciences, San Paolo Hospital, Milan, Italy

## Introduction

- Antiretroviral therapy (ART) induced toxicity has been frequently reported in HIV/HCV co-infected individuals. However, there is conflicting evidence on whether HIV/HCV co-infection has a synergistic effect on ART-induced toxicity.
- One way to evaluate this hypothesis is to compare the risk of ALT elevation associated with the use of ART in HIV/HCV co-infected vs HIV mono-infected populations.

## Objective

- To determine whether use of ART in HIV/HCV co-infected patients is associated with increased hepatotoxicity defined as ALT elevations as compared to HIV mono-infected patients.

## Methods

- We selected individuals in the ICONA Foundation Study cohort with at least one ALT measurement and known current HCV status. We designed a case-control analysis nested in the cohort.
- Cases were defined as individuals who showed liver enzyme elevation (LEE) >5 x upper limit normal at their last clinical observation; controls were participants who showed normal liver enzyme levels after the same time after enrolment in the cohort.
- Controls were matched by a pre-defined set of potential confounders: age {≤20, 21-25, 26-30 to >65}, CD4 count cells/mm<sup>3</sup> {≤350, 351 - 500, >501}, HIV-RNA viral load copies/ml {≤1000, 1001 – 5000 to >100,000} and mode of HIV transmission.
- A conditional logistic regression model was used to evaluate the association between ART exposure and risk of LEE in a univariable model adjusted for matching factors and after further controlling for gender, nationality, alcohol use, smoking status and calendar year of enrolment. Interaction between HIV/HCV co-infection status and ART exposure were also formally assessed.


## Results

- We included 2061 individuals (1:2 matching) with median calendar year of last clinical visit in 2014 (IQR: 2007 - 2015) [Figure 1].
- Overall, median age was 35 (IQR: 31-40), mode of HIV transmission was reported as follows; PWID (32%), MSM (36%), heterosexual (30%) and other/unknown (3%), median CD4 count 386 (IQR: 188-586) cells/mm<sup>3</sup> and HIV-RNA viral load log<sub>10</sub> copies/ml 4.5 (IQR: 3.8 – 5.1).
- Majority were males (70%). Individuals reporting smoking were less in cases than controls 22% and 26% (p=0.03). Proportion of HIV/HCV co-infected individuals was higher in cases than in controls 39% and 29% respectively (p<0.001). Proportion of ART use was higher in cases than controls 79% and 72% respectively (p<0.001) [Table 1].
- In the model without interaction, ART use was associated with an increased risk of LEE [adjusted odds ratio (aOR) 1.87 [95% CI: 1.39-2.53; p<0.001] independently of all factors included [Table 2].
- In the model with the interaction term, the association between co-infection and risk of LEE was 3.76 [95% CI: 1.31 – 10.81] in individuals on ART and 3.17 [95% CI: 2.09 – 4.80] in ART naïve individuals (p=0.69) [Figure 2].

## Conclusion

- Our analysis show no evidence that risk of ALT elevation due to HIV/HCV co-infection is exacerbated by the exposure to ART (3-fold increased risk in both strata).
- Further analyses are needed to investigate the possible effect associated with the use of specific drugs/regimens

Figure 1. Patient selection flow diagram



(Case: Control as 1:2); Matched on age, CD4 cell count, HIV-RNA viral load, and mode of HIV transmission

Table 1. Patient characteristics stratified by ALT elevation status (cases/controls)

Patient characteristics	Elevated ALT N= 687 (%)	No elevated ALT N= 1374 (%)	Total N= 2061 (%)	p-value
<b>Gender,</b>				
Female	195 (28.4%)	427 (31.1%)	622 (30.2%)	0.209
<b>Nationality</b>				
Italian	614 (89.4%)	1242 (90.4%)	1856 (90.1%)	0.466
<b>Smoking status</b>				0.032
No	152 (22.1%)	335 (24.4%)	487 (23.6%)	
Yes	151 (22.0%)	354 (25.8%)	505 (24.5%)	
Unknown	384 (55.9%)	685 (49.9%)	1069 (51.9%)	
<b>Alcohol consumption</b>				0.174
Abstaining	157 (22.9%)	336 (24.5%)	493 (23.9%)	
Moderate	61 (8.9%)	158 (11.5%)	219 (10.6%)	
Hazardous	18 (2.6%)	29 (2.1%)	47 (2.3%)	
Unknown	451 (65.6%)	851 (61.9%)	1302 (63.2%)	
<b>HCV status (time-dependent)</b>				<.001
HCV negative	418 (60.8%)	971 (70.7%)	1389 (67.4%)	
HCV positive	269 (39.2%)	403 (29.3%)	672 (32.6%)	
<b>ART status (time-dependent)</b>				<.001
ART naive	144 (21.0%)	389 (28.3%)	533 (25.9%)	
On ART	543 (79.0%)	985 (71.7%)	1528 (74.1%)	

Table 2. Unadjusted and adjusted odds ratio from fitting a conditional logistic regression model

	Unadjusted OR(95% CI)	p-value	Adjusted OR(95%CI)	p-value
<b>HCV status(time-dependent)</b>				
HCV negative	1.00		1.00	
HCV positive	2.89 (2.10, 3.97)	<.001	2.95 (2.09, 4.16)	<.001
<b>ART status(time dependent)</b>				
ART naive	1.00		1.00	
on ART	1.82 (1.39, 2.37)	<.001	1.87 (1.39, 2.53)	<.001
<b>Gender</b>				
Male	1.00		1.00	
Female	0.83 (0.66, 1.06)	0.134	0.85 (0.65, 1.10)	0.204
<b>Italian</b>				
No	1.00		1.00	
Yes	0.88 (0.64, 1.21)	0.444	0.83 (0.58, 1.20)	0.323
<b>Smoking</b>				
No	1.00		1.00	
Yes	0.95 (0.72, 1.26)	0.732	0.96 (0.70, 1.32)	0.814
Unknown	1.26 (0.99, 1.60)	0.060	1.17 (0.85, 1.61)	0.325
<b>Alcohol</b>				
Abstain	1.00		1.00	
Moderate	0.82 (0.57, 1.18)	0.280	0.74 (0.48, 1.12)	0.152
Hazardous	1.33 (0.70, 2.52)	0.380	1.18 (0.57, 2.44)	0.650
Unknown	1.15 (0.91, 1.45)	0.233	0.99 (0.73, 1.33)	0.934
<b>Calendar year</b>	0.98 (0.96, 1.00)	0.066	0.99 (0.97, 1.02)	0.540

Figure 2: Adjusted odds ratio from fitting a conditional Logistic regression model

